Ophthalmology – Idiopathic Orbital Inflammatory Syndrome (Orbital Pseudotumor)

Basics

Description

Idiopathic orbital inflammatory syndrome (IOIS), historically called orbital pseudotumor, is a noninfectious, non-neoplastic inflammatory disorder of the orbit in which no specific local or systemic cause can be identified.

It is fundamentally a diagnosis of exclusion. Before labeling orbital inflammation as idiopathic, important mimics such as infection, thyroid eye disease, lymphoma, sarcoidosis, IgG4-related disease, granulomatosis with polyangiitis, and metastatic or primary orbital tumors must be considered.

IOIS can involve virtually any orbital structure, either alone or in combination. According to the predominant site, it may present as:

• Orbital myositis
• Dacryoadenitis
• Posterior scleritis
• Diffuse orbital fat inflammation
• Apical orbital inflammation

Some patients have diffuse disease involving several compartments simultaneously.

Epidemiology

The exact incidence and prevalence are uncertain.

IOIS accounts for a minority of orbital inflammatory disorders, historically estimated at approximately 5% of orbital disease in some series.

It most commonly presents between 40 and 60 years of age, but it can occur at virtually any age.

Children may be affected and can present somewhat differently from adults, including a greater tendency toward bilateral disease and systemic symptoms.

Risk Factors

No consistent risk factor has been established.

Some patients have coexisting autoimmune or inflammatory disorders, but in many cases the relationship is uncertain.

Reported associations include:

• Rheumatoid arthritis
• Systemic lupus erythematosus
• Crohn disease
• Ankylosing spondylitis
• Diabetes mellitus

The presence of another autoimmune disorder should prompt careful consideration of whether the orbital disease is truly idiopathic.

Genetics

No specific hereditary pattern has been established.

IOIS is generally considered sporadic.

General Prevention

There is no known primary preventive strategy because the inciting cause remains uncertain.

Prevention of complications depends on:

• Prompt recognition
• Appropriate imaging
• Exclusion of dangerous mimics
• Adequate treatment of inflammation
• Long-term follow-up when the diagnosis remains clinical rather than histologic

Pathophysiology

The underlying mechanism is incompletely understood.

IOIS is thought to represent a heterogeneous group of immune-mediated inflammatory processes involving orbital tissues.

Possible mechanisms include:

• Autoimmune inflammation
• T-cell-mediated immune activation
• Cytokine-mediated tissue injury
• Fibroinflammatory responses

Because different orbital compartments can be involved, IOIS likely represents more than one biological process rather than a single uniform disease.

Chronic or recurrent inflammation may eventually produce fibrosis and permanent restriction of orbital structures.

Etiology

By definition, there is no identifiable specific cause.

Thus, when a definite infectious, neoplastic, autoimmune, vasculitic, or systemic inflammatory disorder is discovered, the diagnosis should be revised accordingly.

Commonly Associated Conditions

Most cases are isolated.

However, patients may have or later develop systemic inflammatory disease.

Reported associations include:

• Crohn disease
• Rheumatoid arthritis
• Systemic lupus erythematosus
• Ankylosing spondylitis
• Other autoimmune disorders

This is one reason long-term follow-up is valuable.

Diagnosis

History

The classic presentation is abrupt onset of painful orbital inflammation.

The most characteristic symptom is:

Periorbital or orbital pain.

Pain is common enough that its absence should make the clinician more cautious about the diagnosis.

Other symptoms include:

• Diplopia
• Blurred vision
• Pain with eye movement
• Eyelid swelling
• Orbital fullness
• Redness
• Proptosis
• Reduced vision in severe disease

The onset is often acute or subacute.

Important Historical Questions

A detailed history should assess for:

• Fever
• Constitutional symptoms
• Sinus disease
• Recent infection
• Immunosuppression
• Previous malignancy
• Autoimmune disease
• Thyroid disease
• Pulmonary symptoms
• Neurologic symptoms
• Previous orbital inflammation
• Trauma or surgery

A complete review of systems is particularly important because apparently idiopathic orbital inflammation may eventually prove to be part of a systemic disorder.

Pediatric Considerations

Children may have:

• Bilateral disease
• Sequential involvement of both orbits
• Fever
• Constitutional symptoms

Because orbital cellulitis is an important and potentially dangerous mimic in children, infection must be carefully excluded before corticosteroid therapy is started.

Physical Examination

A complete ophthalmic and orbital examination is required.

Possible findings include:

• Tender eyelid edema
• Pink-red eyelid erythema
• Conjunctival injection
• Chemosis
• Proptosis
• Painful restricted eye movement
• External ophthalmoplegia
• Reduced visual acuity
• Relative afferent pupillary defect if the optic nerve is involved
• Optic disc swelling
• Choroidal folds
• Choroidal detachment in posterior scleritis

The degree and location of inflammation depend on the affected orbital compartment.

Orbital Myositis

When an extraocular muscle is predominantly involved, patients often present with:

• Acute orbital pain
• Pain worsened by eye movement
• Diplopia
• Restricted ocular motility
• Localized tenderness

Unlike classic thyroid eye disease, IOIS-associated myositis may involve the muscle belly and tendon insertion.

Dacryoadenitis

Lacrimal gland involvement may cause:

• Superotemporal eyelid swelling
• Pain
• S-shaped upper eyelid contour
• Displacement of the globe
• Tenderness over the lacrimal gland

Because the lacrimal gland is a common site for lymphoma, IgG4-related disease, sarcoidosis, and epithelial tumors, the threshold for biopsy is relatively low in atypical or persistent cases.

Posterior Scleritis

Posterior scleritis may occur within the IOIS spectrum.

Features can include:

• Severe deep ocular pain
• Reduced vision
• Pain with eye movement
• Choroidal folds
• Exudative retinal detachment
• Optic disc edema

B-scan ultrasonography may demonstrate the classic T-sign, caused by fluid around the optic nerve adjacent to thickened posterior sclera.

Orbital Apex Disease

Inflammation involving the orbital apex can threaten vision.

Possible findings include:

• Optic neuropathy
• Decreased visual acuity
• Dyschromatopsia
• Relative afferent pupillary defect
• Visual field loss
• Multiple cranial nerve deficits

This presentation often requires urgent treatment and careful exclusion of alternative causes.

Diagnostic Tests and Interpretation

Laboratory Testing

No laboratory test confirms IOIS.

Laboratory studies are mainly used to identify mimicking systemic disorders.

Depending on the presentation, investigations may include:

• CBC with differential
• ESR and CRP
• ANA
• ANCA
• ACE
• Serum protein electrophoresis
• LDH
• Thyroid studies
• IgG4 level
• Infectious testing when indicated

Testing should be directed by history and examination rather than performed indiscriminately.

Imaging

All suspected cases require orbital imaging.

IOIS should not be diagnosed solely from symptoms and examination.

CT

CT may demonstrate:

• Poorly defined soft-tissue inflammation
• Orbital fat stranding
• Enlargement of extraocular muscles
• Lacrimal gland enlargement
• Apical involvement
• Contrast enhancement

Bone destruction is atypical and should raise concern for malignancy, invasive infection, or another alternative diagnosis.

MRI

MRI is particularly useful for defining soft-tissue extent.

Typical inflammatory tissue may show:

• Low to intermediate signal on T1
• Variable signal on T2
• Contrast enhancement after gadolinium

Signal characteristics can vary with the amount of active inflammation versus fibrosis.

More fibrotic disease may appear relatively low signal on T2.

Ultrasonography

Orbital ultrasonography is less frequently used today but remains useful in selected situations.

For suspected posterior scleritis it may reveal:

• Posterior scleral thickening
• Fluid in Tenon’s space
• The characteristic T-sign

Biopsy

Orbital biopsy is not mandatory in every classic case, but it is critical when the presentation is atypical.

Biopsy should be strongly considered when there is:

• Poor or incomplete steroid response
• Steroid dependence
• Recurrent disease
• Painless orbital mass
• Atypical imaging
• Bone erosion
• History of malignancy
• Persistent lacrimal gland enlargement
• Progressive disease despite treatment
• Diagnostic uncertainty

A low threshold for biopsy is particularly appropriate for lacrimal gland disease, because biopsy can often be obtained relatively safely and several important neoplasms may present with inflammatory features.

Pathological Findings

Histopathology is generally nonspecific.

Findings may include:

• Lymphocytes
• Plasma cells
• Histiocytes
• Variable fibroblast proliferation
• Variable fibrosis

The pathology should also be examined for evidence of:

• Lymphoma
• IgG4-related disease
• Granulomatous inflammation
• Vasculitis
• Infection
• Neoplasia

Differential Diagnosis

Important alternatives include:

• Orbital cellulitis
• Thyroid eye disease
• IgG4-related orbital disease
• Sarcoidosis
• Granulomatosis with polyangiitis
• Orbital lymphoma
• Metastatic tumor
• Primary orbital neoplasm
• Tolosa-Hunt syndrome
• Posterior scleritis
• Cavernous sinus disease
• Orbital fungal infection
• Lymphoproliferative disease

The differential diagnosis is especially broad in patients with recurrent, painless, or steroid-resistant disease.

Treatment

Treatment depends on severity and on confidence that infection and malignancy have been excluded.

The traditional first-line treatment is systemic corticosteroid therapy.

Corticosteroids

Oral prednisone has traditionally been started at approximately 1–1.5 mg/kg/day, followed by a gradual taper according to clinical response.

A dramatic improvement in pain and swelling within the first several days is common.

However:

A steroid response does not prove IOIS.

Lymphoma, sarcoidosis, and several other orbital disorders may temporarily improve with corticosteroids.

Therefore, steroid responsiveness should never substitute for appropriate diagnostic evaluation.

Steroid Taper

Relapse may occur during dose reduction.

A slower taper may be necessary when inflammation returns at lower doses.

Repeated rebound inflammation, prolonged steroid dependence, or incomplete response should prompt reconsideration of the diagnosis and often biopsy.

Intravenous Corticosteroids

IV corticosteroids may be used for severe disease, particularly when there is:

• Optic neuropathy
• Orbital apex involvement
• Marked vision loss
• Severe diffuse inflammation

Treatment should be closely monitored because high-dose systemic steroids have substantial metabolic and infectious risks.

NSAIDs

Nonsteroidal anti-inflammatory drugs may be useful in:

• Mild disease
• Steroid tapering
• Patients with recurrent symptoms at very low steroid doses

Some clinicians may try NSAIDs first in limited orbital myositis, although corticosteroids remain more commonly used for significant disease.

Intralesional Corticosteroids

Local corticosteroid injection, such as triamcinolone, may be considered in selected localized lesions, particularly lacrimal gland inflammation.

This is an off-label strategy and carries risks including:

• Globe perforation
• Vascular occlusion
• Elevated IOP
• Skin or fat atrophy
• Local tissue injury

It should be used only by clinicians experienced in orbital injection techniques.

Observation

Mild inflammation may occasionally resolve spontaneously.

Observation can be considered when:

• Symptoms are limited
• Vision is unaffected
• Imaging is reassuring
• Serious alternative diagnoses have been excluded

Close follow-up is still required.

Steroid-Resistant or Steroid-Dependent Disease

Patients who fail corticosteroid therapy should not simply be given progressively stronger immunosuppression without reconsidering the diagnosis.

Where feasible, tissue biopsy should precede long-term immunomodulatory treatment.

Potential steroid-sparing therapies include:

• Methotrexate
• Azathioprine
• Mycophenolate
• Cyclosporine
• Tacrolimus
• Cyclophosphamide in selected severe cases
• Biologic therapy in carefully selected refractory disease

Choice of agent depends on disease pattern, comorbidities, and specialist experience.

Orbital Radiotherapy

Low-dose orbital radiotherapy may be considered in selected cases that are:

• Corticosteroid-resistant
• Corticosteroid-dependent
• Intolerant of systemic immunosuppression

When tissue is safely accessible, biopsy should generally be obtained before radiation treatment.

Surgery

Surgery is primarily used for diagnostic biopsy, rather than complete excision.

Diffuse inflammatory tissue is often poorly demarcated and complete excision may cause:

• Diplopia
• Optic nerve injury
• Ptosis
• Sensory deficits
• Scarring

Therefore, extensive resection is usually inappropriate.

Inpatient Considerations

Most patients can be managed as outpatients.

Admission may be appropriate when:

• High-dose IV corticosteroids are required
• Severe optic neuropathy is present
• Significant comorbidities make systemic steroid therapy unsafe
• Deep orbital biopsy requires postoperative observation
• Infection cannot yet be confidently excluded

Follow-Up

Close follow-up is required during active treatment.

Monitoring should assess:

• Pain
• Visual acuity
• Pupillary function
• Color vision
• Proptosis
• Ocular motility
• Diplopia
• Optic nerve function
• Response to therapy
• Steroid-related adverse effects

Long-term follow-up is advisable even after apparent resolution.

Long-Term Monitoring

Some patients initially labeled as having idiopathic orbital inflammation later develop evidence of a specific systemic or orbital disease.

Therefore, follow-up every 6–12 months after resolution may be reasonable in recurrent or atypical cases.

Particular attention should be paid to:

• Recurrence
• Contralateral orbital involvement
• New systemic inflammatory symptoms
• New lymphadenopathy
• Persistent lacrimal gland enlargement

Patient Education

Patients should understand that IOIS is often a clinical diagnosis of exclusion.

They should be told that:

• Symptoms may recur
• Additional testing or biopsy may eventually become necessary
• Corticosteroid response does not completely exclude tumor or systemic disease
• New visual loss, worsening pain, or recurrent proptosis requires prompt reassessment

Patients receiving corticosteroids should also be counseled about potential complications including hyperglycemia, hypertension, infection, mood changes, osteoporosis, and gastrointestinal effects.

Prognosis

Most patients respond well to therapy and recover without major permanent visual dysfunction.

The prognosis is less favorable when there is:

• Orbital apex involvement
• Optic neuropathy
• Multiple recurrences
• Marked fibrosis
• Delayed diagnosis
• Incomplete response to corticosteroids

Chronic inflammation may produce permanent orbital fibrosis and restriction.

Complications

Potential complications include:

• Permanent diplopia
• Restrictive ophthalmoplegia
• Orbital fibrosis
• Optic neuropathy
• Permanent visual loss
• Ptosis
• Proptosis
• Recurrence
• Steroid toxicity
• Immunosuppressive treatment complications
• Surgical biopsy complications such as hemorrhage, infection, diplopia, sensory loss, ptosis, or rarely visual loss

The most important diagnostic principle is that orbital pseudotumor should remain a diagnosis of exclusion—atypical, recurrent, painless, or steroid-resistant disease warrants renewed investigation and often biopsy.